Viracta Therapeutics, Inc.
VIRX
$0.0217
-$0.0051-19.03%
| Weiss Ratings | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.06 | |||
| Price History | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -20.80% | |||
| 30-Day Total Return | -41.35% | |||
| 60-Day Total Return | -89.72% | |||
| 90-Day Total Return | -85.71% | |||
| Year to Date Total Return | -87.73% | |||
| 1-Year Total Return | -97.91% | |||
| 2-Year Total Return | -98.53% | |||
| 3-Year Total Return | -99.56% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -97.95% | |||
| 52-Week Low % Change | 235.00% | |||
| Price | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.31 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Feb 11, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.07M | |||
| Enterprise Value | -3.16M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.10 | |||
| Earnings Per Share Growth | -11.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.16 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | 0.07 | |||
| Enterprise Value/EBIT | 0.07 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 39.57M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 400 8470 | |||
| Address | 2533 South Coast Highway 101 Cardiff, CA 92007 | |||
| Website | www.viracta.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -66.76% | |||
| Return on Equity | -- | |||
| Income Statement | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -46.77M | |||
| EBIT (TTM) | -47.21M | |||
| Net Income (TTM) | -43.29M | |||
| Net Income Avl. to Common (TTM) | -43.29M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 16.25% | |||
| EPS Diluted (TTM) | -1.10 | |||
| EPS Diluted Growth (Q YOY) | 18.11% | |||
| Balance Sheet | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 21.13M | |||
| Cash Per Share (Q) | $0.53 | |||
| Total Current Assets (Q) | 21.80M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -6.62M | |||
| Current Ratio (Q) | 0.763 | |||
| Book Value Per Share (Q) | -$0.17 | |||
| Total Assets (Q) | 21.96M | |||
| Total Current Liabilities (Q) | 28.58M | |||
| Total Debt (Q) | 16.91M | |||
| Total Liabilities (Q) | 28.58M | |||
| Total Common Equity (Q) | -6.62M | |||
| Cash Flow | VIRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 43.33M | |||
| Cash from Financing (TTM) | -8.26M | |||
| Net Change in Cash (TTM) | 271.00K | |||
| Levered Free Cash Flow (TTM) | -23.36M | |||
| Cash from Operations (TTM) | -34.80M | |||
